Transfusion-associated graft-vs-host disease in patients with malignancies. Report of two cases and review of the literature

Decoste, S. D.

doi:10.1001/archderm.126.10.1324

Cited by 9 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Graft vs. host disease is an expected complication of bone marrow transplantation, but has also been reported after transfusion of irradiated and nonirradiated blood products, in patients with immunodeficiency syndromes, and patients receiving chemotherapy (16)(17)(18)(19), and recipients of solid-organ transplants (4)(5)(6)(7)(8). Though recipients of small bowel transplants are theoretically at high risk owing to the amount of lymphoid containing tissue in the graft (20), the incidence and management of this complication in small bowel transplantation in humans has not been well described.…”

Section: Discussionmentioning

confidence: 99%

Graft Versus Host Disease in Intestinal Transplantation

Mazariegos¹,

Abu‐Elmagd²,

Jaffe³

et al. 2004

American Journal of Transplantation

135

119

View full text Add to dashboard Cite

Our aim was to analyze the clinical course and outcome of patients with graft vs. host disease (GVHD) after intestinal transplantation (ITx). All patients receiving ITx between May, 1990 and December, 2003 were retrospectively reviewed for evidence of GVHD. Two hundred and fifty patients underwent ITx during the study period. Graft vs. host disease was suspected clinically in 23 patients on the clinical basis of presentation such as skin rash, ulceration of oral mucosa, diarrhea, lymphadenopathy, or native liver dysfunction. Fourteen (eight children and six adults) patients (5.6% of total patient population) had GVHD confirmed by histopathological criteria including keratinocyte necrosis (n = = 9), epithelial apoptosis of the native gastrointestinal tract (n = = 4), and epithelial cell necrosis of oral mucosa (n = = 1). Donor-cell tissue infiltration or extensive peripheral blood donor-cell chimerism was documented on seven occasions. The majority of cases of GVHD resolved with steroid administration and optimization of tacrolimus immunosuppression.The incidence of histologically proven GVHD after clinical intestinal transplantation is 6.5% (8/122) in children and 4.7% (6/128) in adults. Successful clinical management requires a high index of suspicion to minimize morbidity and mortality. Diagnostic and treatment strategies based on this experience are proposed.

show abstract

Section: Discussionmentioning

confidence: 99%

Graft Versus Host Disease in Intestinal Transplantation

Mazariegos¹,

Abu‐Elmagd²,

Jaffe³

et al. 2004

American Journal of Transplantation

135

119

View full text Add to dashboard Cite

show abstract

“…The majority of cases of TA‐GVHD have been reported in patients with haematological malignancies (Kessinger et al , 1987). Patients with Hodgkin's disease, with its associated immune deficiency state, are at highest risk of developing this disease (Dinsmore et al , 1980; von Fliedner et al , 1982; Burns et al , 1984; Decoste et al , 1990). Patients with other diseases, such as the acute leukaemias, that are treated with intensive chemotherapy have been reported to develop TA‐GVHD (Lowenthal et al , 1981; Nikoskelainen et al , 1983).…”

mentioning

confidence: 99%

Transfusion‐associated graft‐versus‐host disease

Schroeder

2002

Br J Haematol

135

View full text Add to dashboard Cite

“…Even immunocompetent patients who share an HLA antigen haplotype with HLA antigen-homozygous blood donors appear to be at risk for transfusionassociated GVHD, 5 such as noted in relatives or members of inbred populations found in some parts of Japan. It is reasonable to suppose that residual lymphocytes from the donor can induce transfusion-associated GVHD after peripheral blood transplantation since as few as 5 ϫ 10 4 lymphocytes per kilogram may be sufficient to induce transfusion-associated GVHD under certain circumstances, according to Hull et al 6 However, considering the fact that most of the cases of transfusionassociated GVHD occur about 2 to 30 days after transfusion, 7 it would be unique that the skin lesions in our present patient developed so late. We cannot con-sider them as usual transfusion-associated GVHD.…”

Section: Commentmentioning

confidence: 99%

Columnar Epidermal Necrosis

Saijo

Honda²,

Sasahara³

et al. 2000

Arch Dermatol

View full text Add to dashboard Cite

Background: In 1978, the first case of columnar epidermal necrosis was reported in a 6-year-old boy. There were scaly, partially vesicular or crusty, erythematous lesions mainly involving the extremities that histopathologically showed peculiar features of focal, total epidermal necrosis accompanied by a lichenoid tissue reaction. He developed the skin eruption after receiving a blood transfusion from his mother when he showed debility induced by vaccination with an alternated live measles virus vaccine. The lesions rapidly regressed after sun exposure. To our knowledge, there has been no report of a similar case despite such unique features. Observation: We encountered a similar case of columnar epidermal necrosis in a 15-year-old Japanese girl with chronic graft-vs-host disease; the lesions occurred 3 months after the transfusion of peripheral blood stem cells from her HLA antigen-matched brother. However, there was no exacerbation of liver dysfunction, diarrhea, or bone marrow aplasia. The peculiar cutaneous lesions responded well to topical phototherapy.

show abstract

Transfusion-associated graft-vs-host disease in patients with malignancies. Report of two cases and review of the literature

Cited by 9 publications

References 0 publications

Graft Versus Host Disease in Intestinal Transplantation

Graft Versus Host Disease in Intestinal Transplantation

Transfusion‐associated graft‐versus‐host disease

Columnar Epidermal Necrosis

Contact Info

Product

Resources

About